Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Shares Outstanding (Diluted Average) (2020 - 2024)

SELLAS Life Sciences (SLS) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $68.3 million as the latest value for Q3 2024.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 154.98% to $68.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was $68.3 million, a 154.98% increase, with the full-year FY2023 number at $27.8 million, up 43.21% from a year prior.
  • Shares Outstanding (Diluted Average) was $68.3 million for Q3 2024 at SELLAS Life Sciences, up from $51.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $68.3 million in Q3 2024 to a low of $6.7 million in Q2 2020.
  • A 5-year average of $23.8 million and a median of $19.8 million in 2022 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 6.86% in 2022, then surged 154.98% in 2024.
  • SELLAS Life Sciences' Shares Outstanding (Diluted Average) stood at $8.0 million in 2020, then surged by 94.07% to $15.5 million in 2021, then increased by 25.29% to $19.4 million in 2022, then surged by 43.21% to $27.8 million in 2023, then surged by 145.72% to $68.3 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Shares Outstanding (Diluted Average) are $68.3 million (Q3 2024), $51.2 million (Q2 2024), and $44.8 million (Q1 2024).